The conversation is about frustration over the delay in phase 2 results for a hair loss treatment called GT20029. One user suspects the treatment may have failed.
Finasteride has shown great results for hair loss. The discussion also inquires about the effectiveness and side effects of Low-Level Laser/Light Therapy (LLLT).
The user experienced eyebrow hair loss and tried various treatments, including Minoxidil, a Capsaicin-based product, Latanoprost, Bimatoprost, Castor Oil, and Travoprost. Despite initial setbacks and a brutal shedding phase, they eventually saw positive results with Travoprost, encouraging others not to give up on treatments.
OP is considering Bicalutamide for female AGA and TE but is concerned about its side effects and effectiveness compared to Finasteride. OP is also using Minoxidil and Spironolactone but is experiencing significant shedding and is unsure if it's androgen-driven or due to Minoxidil changes.
Chinese company gets green light for Pyrilutamide Phase II trial for androgenetic alopecia. Androgen receptors downregulate in androgen deficient environments.
AnagenInc is ready to produce a hair loss treatment called GT20029 if there is enough demand. People are discussing combining it with other treatments like finasteride and minoxidil, and some are concerned about the legitimacy and safety of gray market products.
CB-03-01 is a topical anti-androgen with low absorption, offering potential as a side-effect-free alternative to Finasteride/Dutasteride for hair loss. It's in stage 2 clinical trials for acne and showing promise for male pattern baldness.
A 20-year-old male is frustrated with his dermatologist for refusing to prescribe DHT blockers like finasteride or dutasteride, instead pushing for a hair transplant despite ongoing hair thinning. The user feels dismissed and unreasonably treated, and is advised by another user to find a better dermatologist and consider finasteride or dutasteride for effective treatment.
MCL-1 protein may help maintain hair follicles in the growth phase and prevent miniaturization. There is interest in experimental treatments like exosomes, peptides, or stem cell serums to upregulate MCL-1 for hair loss, especially for those not using minoxidil or finasteride.
The conversation discusses various treatments for hair loss, including minoxidil, finasteride, and topical dutasteride, with users debating their effectiveness and side effects. Despite the treatments, many believe androgenetic alopecia (AGA) ultimately prevails in the long term.
The user is using minoxidil, finasteride, dutasteride, and clobetasol, along with needling, to combat hair loss. They are considering stopping treatment if no improvement is seen.
Combining dutasteride and an aromatase inhibitor may increase testosterone levels significantly, potentially enhancing athletic performance but also posing health risks like elevated blood pressure and worsened cholesterol. The user is experimenting with dutasteride, anastrozole, minoxidil, and ketoconazole shampoo to manage hair loss and estradiol levels, while monitoring side effects and hormone levels.
KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.
The conversation discusses diffuse unpatterned alopecia (DUPA) and its possible causes, including sensitivity to DHT, not being androgenic alopecia, being diffuse alopecia areata, or hormonal issues. Treatments mentioned include topical melatonin, Clobetasol Propionate for alopecia areata, and the lack of results from using finasteride, dutasteride, and minoxidil.
The user is considering microneedling versus a hair transplant (HT) for crown hair loss while currently using dutasteride and oral minoxidil. They are hesitant about microneedling due to potential scarring but are open to trying it before deciding on a hair transplant.
The user is using a hair loss treatment regimen including Avodart (dutasteride), oral minoxidil, LLLT caps, vitamins, and ketoconazole shampoo, and is considering adding dermarolling and RU58841. They are experiencing unwanted body hair growth from minoxidil and are planning for a future hair transplant.
A user experienced significant hair regrowth from Xeljanz after severe alopecia but can no longer afford it. They are seeking ways to obtain the medication despite its high cost and potential side effects.
ET-02 (RS 5441) shows promising results for hair growth, performing better in humans than in mice. There is debate over the effectiveness compared to minoxidil, with some users wanting more detailed data.
The conversation is about a user experiencing positive hair regrowth results using 1mg of dutasteride, 10% minoxidil, and occasional microneedling, after unsatisfactory results with finasteride. Other users express interest in switching to dutasteride and share similar sentiments about finasteride.
The conversation discusses the potential of a new hair loss treatment, GT20029, which may prevent hair loss by destroying androgen receptors on the scalp. Users express hope for the treatment's success and speculate on its usage routine, effectiveness, and possible side effects.
The user had a hair transplant with Estenove, rating the overall experience 6/10 due to logistical issues, unmet expectations, and dissatisfaction with the results. They advise against pricier packages and express regret over the asymmetrical hairline, despite good customer service and post-op care.
Evidence-based treatments for androgenic alopecia, such as minoxidil, finasteride, low-level laser light therapy, dutasteride, platelet-rich plasma, and topical ketoconazole. It discusses the efficacy, safety, and mechanism of action of these treatments, as well as future developments in understanding this polygenic condition.
The review discusses traditional hair loss treatments like minoxidil and finasteride, and newer options like Low-Level Laser Therapy, microneedling, and platelet-rich plasma for androgenetic alopecia. It highlights the need for more high-quality trials to assess these treatments' effectiveness and standardized protocols for emerging therapies.
The conversation is about considering pyrilutamide 1% as an alternative treatment for hair loss due to intolerance to 5-alpha reductase inhibitors. Some users suggest it might be effective, while others view it as a temporary solution.
A user shared their experience with a hair and beard transplant in Istanbul, performed by Dr. Selahattin Tulunay, noting successful results after 12 months. The procedure cost 5000 €, and the user is open to questions about combining procedures or traveling for surgery.
A new drug, PP405, is being discussed as a potential cure for baldness, with hopes it could be more effective than Minoxidil and Finasteride. Users are skeptical about its effectiveness and the need for lifelong use.
The conversation discusses purchasing experimental hair loss treatments KX-826, AHK-Cu, and PTD-DBM, with the user already using Minoxidil and having side effects from Finasteride. Concerns about the legitimacy of certain suppliers and the authenticity of products like pp405 are also mentioned.
The user believes that combining alfatrodial and fluridil with minoxidil effectively maintains hair, based on their 7-year experience. They suggest this combination for those who can't tolerate finasteride.
The user is considering adding Alfatradiol or Pyralutamide to their current hair loss treatment of oral Dutasteride and Minoxidil. They are seeking advice on experiences and purchasing options for these products in the US.